• Pieris AG
  • Zeppelinstraße 3
  • 85399 Halbergmoos
  • Deutschland
  • Phone: +49 (0) 8161 / 141 14-00
  • Fax: +49 (0) 8161 / 141 14-44
  • moc.ga-sireip@ofni

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company and expects to file an IND application for its first therapeutic Anticalin at the beginning of 2008.